Two separate membrane-bound antigens on human glioma cells in tissue culture detected with sera from glioma patients by immunofluorescence

Intracellular Serum Proteins in Cerebral Gliomas and Metastatic Tumours: An Immunoperoxidase Study

“…Insignificant amounts of Ig are produced intrinsically in the brain (Connolly, 1972) and there is no evidence that astrocytes or glioma cells synthesize Ig. Circulating antitumour antibodies have been detected in the serum of patients with gliomas (Solheid, Lauro & Palladini, 1976), but the range of serum proteins identified in the reactive astrocytes and glioma cells does include albumen i n addition to immunoglobulins; thus it is unlikely that the proteins are adhering to the cell surface by specific immune mechanisms. Therefore, exuded serum in the extracellular space of the tumour or oedema fluid in the surrounding brain remain the most probable sources of the intracellular Ig and albumen in the astrocytic glioma cells and reactive astrocytes.…”

Human glioma tumour-associated antigens

“…Glioblastomas, astrocytomas, and fetal brain were found to have a common antigen, an al-lipoprotein, the level of which increased with increasing anaplasia of the tumour [39]. Solheid et al [37] investigated the reactivity of glioma patients' sera with cultured glioma and normal glial cells, using an immunofluorescence assay. He described two antigens: one common to glioblastomas, astrocytomas, and reactive normal glial tissue, and the other common to glioblastomas and reactive normal glial tissue, only.…”

Evaluation of the humoral response of glioma patients to a possible common tumor‐associated antigen(S)

“…Reports from several investigators have suggested the presence of tumor-associated antigens on human glioma cells. These antigens were identified by heteroantisera raised against tumor homogenates and cultured cells derived from these tumors (Coakham and Lakshmi, 1975;Kehayov, 1976;Wahlstrom et al, 1974;Wikstrand et al, 1977) or by demonstration of anti-tumor antibodies in glioma patients' sera (Kornblith et al, 1974;Kumar and Taylor, 1973;Jagarlamoody et al, 1971;Sheik et al, 1977;Solheid et al, 1976;Trouillas, 1971;Wahlstrom et af., 1973). The cellular response of the patients was demonstrated by delayed hypersensitivity reactions to tumor extracts in skin tests (Febvre et al, 1972;Hitchcock et al, 1977;VBnky et al, 1974) and by lymphocyte stimulation or cytotoxicity using tumor cells as stimulators or targets (Brooks et al, 1974;Ciembroniewicz and Kolar, 1969;Eggers, 1972;Kumar and Taylor, 1973;Kumar et al, 1973;Woosley et al, 1977;Levy et al, 1972;Levy, 1973).…”